TScan Therapeutics Announces Updates to its Board of Directors
June 14 2024 - 7:00AM
TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage
biopharmaceutical company focused on the development of T cell
receptor (TCR)-engineered T cell (TCR-T) therapies for the
treatment of patients with cancer, today announced changes to its
Board of Directors. Garry A. Nicholson has been appointed to the
Company’s Board of Directors. In addition, Timothy Barberich has
retired as a Member and Chair of the Board of Directors. Current
board member Stephen Biggar, M.D., Ph.D., will assume the role of
Chair of the Board of Directors.
“We are pleased to welcome Garry to our Board of
Directors. He has a breadth of experience in oncology development
and commercialization spanning more than 35 years, including
serving as president of Pfizer Oncology where he led its global
oncology franchise,” said Gavin MacBeath, Ph.D., Chief Executive
Officer. “Garry has extensive expertise in operations, sales,
regulatory strategy, and commercialization, and we look forward to
working with him as we advance our clinical programs toward pivotal
studies.”
“I am delighted to be joining TScan’s Board and
look forward to working with the leadership team to further advance
the progress of this company and its mission of bringing
life-changing therapies to patients suffering from cancer. My
previous experience across commercialization, operations,
regulatory affairs and launch strategy will help support the growth
of TScan and the advancement of this innovative pipeline,” said Mr.
Nicholson.
“We all wish Tim well as he retires from the
Board. He has been an esteemed member of the Board since 2019 and
as Chair of the Board since 2021. TScan has benefitted from Tim’s
more than 40 years’ experience in pharmaceutical and medical device
companies, and we appreciate his contributions and insights that
have helped us grow from a discovery-stage organization into a
clinically focused company since our inception,” added Dr.
MacBeath. “Steve has served on the Board of TScan since 2021, and
we welcome him to this new leadership role.”
Mr. Nicholson has more than 35 years of
pharmaceutical and biotech oncology experience. Mr. Nicholson
currently serves as chairman of the board of directors for G1
Therapeutics, Day One Biopharmaceuticals and Abdera Therapeutics.
He also previously served on the board of directors for Turning
Point Therapeutics, Five Prime Therapeutics, Tmunity and TESARO
prior to their acquisitions by large pharmaceutical companies. As
former president of Pfizer Oncology, his responsibilities included
global commercialization, sales, clinical development, regulatory
strategy and business development for Pfizer’s oncology portfolio.
Earlier in his career, Mr. Nicholson held various leadership
positions in the oncology division of Eli Lilly and Company,
including global oncology platform leader. He has also served as
president and CEO of XTuit Pharmaceuticals. Mr. Nicholson earned a
B.S. in Pharmacy from the University of North Carolina at Chapel
Hill and an M.B.A. from the University of South Carolina.
About TScan Therapeutics,
Inc.
TScan is a clinical-stage biopharmaceutical
company focused on the development of T cell receptor
(TCR)-engineered T cell (TCR-T) therapies for the treatment of
patients with cancer. The Company’s lead TCR-T candidates, TSC-100
and TSC-101, are in development for the treatment of patients with
hematologic malignancies to prevent relapse following allogeneic
hematopoietic cell transplantation. The Company is also developing
TCR-T candidates for the treatment of various solid tumors. The
Company has developed and continues to expand its ImmunoBank, the
Company’s repository of therapeutic TCRs that recognize diverse
targets and are associated with multiple HLA types, to provide
customized multiplex therapeutic TCR-Ts for patients with a variety
of cancers.
Forward-Looking Statements
This release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995, including, but not limited to, express or implied
statements regarding the Company’s plans, progress, and timing
relating to the Company’s hematologic malignancies and solid tumor
program, including the progress of such programs being indicative
or predictive of the success of such program; the potential
benefits of any of the Company’s proprietary platforms,
multiplexing, or current or future product candidates in treating
patients; and the Company’s goals and strategy. TScan intends such
forward-looking statements to be covered by the safe harbor
provisions for forward-looking statements contained in Section 21E
of the Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995. In some cases, you can identify
forward-looking statements by terms such as, but not limited to,
“may,” “might,” “will,” “objective,” “intend,” “should,” “could,”
“can,” “would,” “expect,” “believe,” “anticipate,” “project,”
“target,” “design,” “estimate,” “predict,” “potential,” “plan,” “on
track,” or similar expressions or the negative of those terms. Such
forward-looking statements are based upon current expectations that
involve risks, changes in circumstances, assumptions, and
uncertainties. The express or implied forward-looking statements
included in this release are only predictions and are subject to a
number of risks, uncertainties and assumptions, including, without
limitation: the beneficial characteristics, safety, efficacy,
therapeutic effects and potential advantages of TScan’s TCR-T
therapy candidates; TScan’s expectations regarding its preclinical
studies being predictive of clinical trial results; TScan’s
recently approved INDs being indicative or predictive of bringing
TScan closer to its goal of providing customized TCR-T therapies to
treat patients with cancer; the timing of the launch, initiation,
progress, expected results and announcements of TScan’s preclinical
studies, clinical trials and its research and development programs;
TScan’s ability to enroll patients for its clinical trials within
its expected timeline; TScan’s plans relating to developing and
commercializing its TCR-T therapy candidates, if approved,
including sales strategy; estimates of the size of the addressable
market for TScan’s TCR-T therapy candidates; TScan’s manufacturing
capabilities and the scalable nature of its manufacturing process;
TScan’s estimates regarding expenses, future milestone payments and
revenue, capital requirements and needs for additional financing;
TScan’s expectations regarding competition; TScan’s anticipated
growth strategies; TScan’s ability to attract or retain key
personnel; TScan’s ability to establish and maintain development
partnerships and collaborations; TScan’s expectations regarding
federal, state and foreign regulatory requirements; TScan’s ability
to obtain and maintain intellectual property protection for its
proprietary platform technology and our product candidates; the
sufficiency of TScan’s existing capital resources to fund its
future operating expenses and capital expenditure requirements; and
other factors that are described in the “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and
Results of Operations” sections of TScan’s most recent Annual
Report on Form 10-K and any other filings that TScan has made or
may make with the SEC in the future. Any forward-looking statements
contained in this release represent TScan’s views only as of the
date hereof and should not be relied upon as representing its views
as of any subsequent date. Except as required by law, TScan
explicitly disclaims any obligation to update any forward-looking
statements.
Contacts
Heather SavelleTScan Therapeutics, Inc.VP, Investor
Relations857-399-9840hsavelle@tscan.com
Maghan MeyersArgot
Partners212-600-1902TScan@argotpartners.com
TScan Therapeutics (NASDAQ:TCRX)
Historical Stock Chart
From Sep 2024 to Oct 2024
TScan Therapeutics (NASDAQ:TCRX)
Historical Stock Chart
From Oct 2023 to Oct 2024